Teleflex Incorporated rebounded from lows after announcing a $2.03B divestiture of Acute Care, Interventional Urology, and OEM businesses. TFX will use $1B of net proceeds for share buybacks, reducing pro forma net debt to $1.5B, but revenue impact remains ambiguous. Shares now trade at 10x adjusted earnings, with market reaction positive despite uncertainty around divested revenue figures.
Teleflex Incorporated ( TFX ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:00 AM EST Company Participants Liam Kelly - Chairman, President & CEO Conference Call Participants Matthew Taylor - Jefferies LLC, Research Division Presentation Matthew Taylor Jefferies LLC, Research Division Great. Thanks for joining us here for our next session.
Explore Teleflex's (TFX) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Liam J. Kelly CEO | XSTU Exchange | US8793691069 ISIN |
| US Country | 14,100 Employees | 14 Nov 2025 Last Dividend | 17 Jun 1997 Last Split | 18 Feb 1988 IPO Date |
Teleflex Incorporated is a global leader in the development, manufacturing, and supply of single-use medical devices for diagnostic and therapeutic procedures in critical care and surgical applications. The company has a rich history dating back to 1943 and is headquartered in Wayne, Pennsylvania. Serving hospitals, healthcare providers, medical device manufacturers, and the home care market, Teleflex aims to improve the health and quality of life of patients worldwide with its innovative medical technologies.